No Data
No Data
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Climbs 5.8% This Week, Taking Five-year Gains to 79%
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) shareholders might be concerned after seeing the share price drop 13% in the last month. But that doesn't change the fact that the
Jiangsu Wu Zhong (600200): Revenue increased 15% in 24Q1 and expected to release AESTHEFILL baby acupuncture
Losses decreased year over year in 2023, and 2024Q1 has not reversed losses. In 2023, the company achieved revenue of 2.24 billion yuan (YoY +10.6%, same below), net profit attributable to mother -0.7 billion yuan (loss narrowing), net profit not attributable to mother
Shanghai Securities released a research report on April 28 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's medical and aesthetic product Aesofei has been officially approved and is
Shanghai Securities released a research report on April 28 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's medical and aesthetic product Aesofei has been officially approved and is expected to be marketed quickly; 2) increasing investment in independent research and development to further lay out the field of recombinant collagen. (Mainichi Keizai Shimbun)
BOC Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's revenue side performance is growing steadily, and the gross margin of the pharm
BOC Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's revenue side performance is growing steadily, and the gross margin of the pharmaceutical sector business is under downward pressure in 2023; 2) Actively strengthening the medical and aesthetic layout, and the medical and aesthetic business approved by AestheFill can be expected in the future. (Mainichi Keizai Shimbun)
Minsheng Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a careful recommendation rating. The main reasons for the rating include: 1) the pharmaceutical business contributes the main revenue, and the gro
Minsheng Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a careful recommendation rating. The main reasons for the rating include: 1) the pharmaceutical business contributes the main revenue, and the growth of the medical and aesthetic business is worth looking forward to; 2) AestheFill polylactic acid facial fillers were approved for sale, focusing on the progress of the promotion of recycled materials; 3) focusing on high-end injectable medical and aesthetic products to enrich the product pipeline. (Mainichi Keizai Shimbun)
Deep* Company* Jiangsu Wuzhong (600200): Revenue side growth is steady, medical and aesthetic products approved for listing can be expected in the future
Jiangsu Wuzhong achieved operating income of 2,240 billion yuan (+10.55%) in 2023, and realized net profit of -72 million yuan to mother. 2024Q1 The company achieved revenue of 703 million yuan in a single quarter (+14.9 million yuan)
No Data